Status:
COMPLETED
Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
Lead Sponsor:
U.S. Army Medical Research and Development Command
Collaborating Sponsors:
United States Army Medical Materiel Development Activity
Conditions:
Dengue
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
Detailed Description
Dengue is a desease that affects 100 million people throughout the world mainly in tropical countries in the South Pacific, Asia, the Caribbean, and Africa. The disease often presents with high fever,...
Eligibility Criteria
Inclusion
- Available to participate for the duration of the study (approximately 12 months)
- Completion and review of knowledge assement quiz
Exclusion
- Pregnant (by history or as ascertained by pregnancy test) or lactating female
- Female who intends to become pregnant during the study
- Plan to have elective surgery during the study period
- HIV infection
- Known immunodeficiency or currently receiving immunosuppressive therapy (inhaled and topical steroids are allowed)
- History of splenectomy
- Administration of a vaccine not foreseen by the study protocol during the period starting 30 days before each dose of vaccine and ending 30 days after vaccination
- Evidence of active (acute or chronic) hepatitis B or C infection
- Autoimmune diseaseor subjects who describe a first-degree relative with clearly documented autoimmune disease
- Acute or chronic, clinically significant cardiac, pulmonary, hepatic, or renal abnormality, as determined by physical examination or basic laboratory screening
- Clinical or laboratory evidence of significant anemia
- History of flavivirus infection or previous receipt of flavivirus vaccine
- Positive serology for flaviviruses (all four dengue virus serotypes, Japanese encephalitis, Yellow fever virus, and West Nile virus), HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment
- Use of any investigational or non-registered drug or vaccine other than the study vaccine within 60 days preceding the first dose of study vaccine, or planned use during the study period.
- Previous history of allergic or anaphylactic reaction to any vaccine
- Planned travel to areas with endemic dengue during the study period
- Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00290147
Start Date
January 1 2006
End Date
April 1 2009
Last Update
June 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Walter Reed Army Institute of Research, Bldg 503
Silver Spring, Maryland, United States, 20910